Celebrating Breast AI Innovation, Clinical Performance and Collaboration at ECR 2025
iCAD is capitalizing on 20+ years of innovation in breast health AI. As the first to bring AI-powered DBT detection to market, iCAD continues to lead the way with wide-ranging AI solutions, cloud-enabled connectivity, and next generation algorithms that are transforming patient care and breast health for the future, including Cancer Detection, Density Assessment, and image-based Risk Evaluation1.
iCAD captured attention by highlighting the clinical efficacy of ProFound AI® Breast Health Suite, unveiling real-world clinical utility data, delivering expert-led clinical AI presentations, and offering insights into the future of breast cancer screening.
From unveiling cutting-edge solutions and announcing strategic and commercial partnerships, this week was a celebration of innovation, collaboration, and commitment to improving patient care.
Here’s a look back at how we celebrated progress, partnerships, and the future of breast health care.
Clinical Expertise + iCAD in the Spotlight
iCAD Showcased Six AI-Powered Research Presentations at ECR. Led by research collaborators, these studies underscore iCAD’s commitment to delivering artificial intelligence (AI) powered solutions to advance personalized risk assessment, enhance early detection, and optimize breast imaging workflows.
Yinhao Ren, PhD, Senior AI Research Scientist, iCAD, Inc.
EPOS: C-22811 – Rapid Prototyping of a Breast Arterial Calcification Detection Algorithm with Human-in-the-Loop Annotation
Introduced a novel AI-driven BAC detection model designed to enhance cardiovascular risk assessment. Developed using a dataset of 14,337 DBT exams, the model achieved an AUC of 0.980 on an enriched validation set and 0.986 when evaluated by MQSA-certified radiologists. By incorporating human-in-the-loop annotation, the model demonstrated improved accuracy and clinical relevance, reinforcing the role of AI in streamlining dataset curation and optimizing detection performance.
Kristina Bojanić, Osijek / Croatia
EPOS: C-12955 – Breast cancer detection with AI: will expectations finally meet reality?
Study of 10,316 women screened with FFDM highlighting potential of AI-powered breast cancer screening, evaluating iCAD’s ProFound AI v3.0 in conjunction with contrast-enhanced mammography (CEM). The findings suggest that integrating AI with CEM can improve the detection and characterization of breast lesions, helping radiologists differentiate between benign and malignant cases more effectively. With its ability to enhance diagnostic confidence and streamline workflows, AI continues to play a critical role in advancing breast cancer detection, particularly for patients with dense breast tissue.
Andrea Nitrosi, Reggio Emilia / Italy
RPS: 705 – Adding artificial intelligence (AI) case scoring in a breast screening programme to optimize reading workflow and workload: a retrospective study
Retrospectively evaluated a strategy to optimize reading workflow and readers’ workload based on the iCAD Case Malignancy Score (CMS).
Marcel Blum, St. Gallen, Switzerland
PS: 705 – Optimal utilization of an AI diagnostic software in a mammography screening program in Switzerland
Evaluated ProFound AI in the screening process of the organized mammography screening program (MSP) “donna”. Aimed to identify the optimal utilization of ProFound AI in the MSP regarding its effectiveness (sensitivity and specificity) and its influence on required resources.
Mikael Eriksson, Karolinska institutet (2025 Best Research Presentation Award)
RPS: 1002 – A 10-year Image-derived AI Risk Model for Use in Primary Prevention of Breast Cancer
Explored the role of artificial intelligence in breast imaging categories: artificial intelligence, breast, imaging methods, research.
Emily F. Conant, MD, University of Pennsylvania
RPS: 2202 – Short-term Risk Prediction of Breast Cancer Comparing Risk Tools for Digital Mammography and Digital Breast Tomosynthesis in U.S. Screening Populations.
Evaluated iCAD’s AI-based risk model across digital breast tomosynthesis (DBT) and digital mammography (DM). iCAD’s AI-powered risk model demonstrated a significant improvement in accuracy, achieving an AUC of 0.75 with DBT compared to 0.71 with DM (p<0.01). The model identified 48% of future breast cancers with DBT, outperforming DM, which detected 40% (p<0.01). These findings highlight the potential of DBT-based AI risk assessment in identifying high-risk individuals earlier, supporting more personalized screening strategies.
“The data presented at ECR 2025 highlight the critical role AI can play in advancing early disease detection and improving patient outcomes. By enhancing breast cancer risk assessment and expanding into breast arterial calcification detection, we are equipping clinicians with more precise, data-driven tools that support proactive, personalized care. These findings further validate the strength of our AI technology and its potential to impact both breast cancer screening and broader women’s health initiatives. As AI adoption in healthcare continues to grow, iCAD remains committed to delivering innovative solutions that empower providers and improve lives.”
Dana Brown
President and CEO, iCAD
Partnerships and Collaboration
Distribution Partners and Customers from throughout Europe and Middle East:
ECR is a unique opportunity to connect in person with our partners who distribute the ProFound AI Breast Health Suite throughout the world. We also talked with many of their customers who discovered how iCAD’s AI solutions could help them maximize early cancer detection and improve clinical outcomes. This year, we were happy to talk in person with the >15 distribution partners who stopped by the iCAD booth!
Platform & Channel Partners:
We are thrilled to offer our customers the flexibility of deployment through our platform & channel partners who make the ProFound AI Breast Health Suite seamlessly accessible to all medical facilities. Our discussions highlighted how combining AI with advanced imaging systems enhance diagnostic precision and efficiency.
At ECR, iCAD announced a new partnership with Koios Medical, a leader in AI-driven ultrasound cancer diagnosis. This new strategic reseller partnership delivers a comprehensive, multi-modality AI suite for breast cancer detection. This collaboration integrates iCAD’s ProFound AI® Breast Health Suite for mammography with Koios SmartUltrasound™, providing radiologists with an AI-powered pathway from screening to diagnosis.
AI in the Sky: Celebrating Partnerships for AI-driven Innovation in Breast Health.
iCAD welcomed its global partners for a wonderful evening to celebrate our shared partnerships and the groundbreaking strides we are making in advancing AI-driven innovations in breast health and patient care.
ProFound Cloud for AI Deployment
iCAD’s ProFound Cloud-based Software as a Service (SaaS) model, offers healthcare providers flexible, scalable access to iCAD’s ProFound full suite of solutions, including DBT Detection, 2D Detection, Density Assessment, and Risk1. The model supports exam-based pricing, allowing facilities to pay only for what they use, while ensuring seamless integration with existing workflows and compliance with healthcare systems and PACS platforms.
Everyone was excited to see the real-world benefits our customers are experiencing processing ProFound AI in the cloud when reading mammograms. The first 200,000 cases customers read have seen an incredible 60% faster processing time compared to running on their local on-premises server.
Blog: Revolutionizing AI Breast Cancer Detection: Speed, Scalability, and Security.
It’s About Time.
To elevate breast health with precision and clarity.
Empower your patients with iCAD’s AI-powered solutions, delivering faster, more precise insights to help you deliver exceptional care today—and tomorrow.
Learn how iCAD’s AI solutions can elevate your approach to breast health.
Don’t miss the opportunity to improve diagnostic precision! Schedule your consultation today.
References:
1. ProFound Detection V4 is FDA Cleared. ProFound AI V3 is FDA Cleared, CE Marked, and Health Canada Licensed. PowerLook Density Assessment is FDA Cleared, CE Marked, and Health Canada Licensed. ProFound AI Risk is CE Marked and Health Canada Licensed, is not FDA Cleared, and is only available in the US for investigational use.